Lilly Posts Higher Drug Sales, Plans to Increase Dividend
- Diverse pipeline will help revenue growth over next decade
- Adjusted earnings of 86 cents a share match analyst estimates
Eli Lilly CEO: Getting Back to Annual Dividend Increase
This article is for subscribers only.
Eli Lilly & Co. posted second-quarter earnings that matched analysts’ estimates as revenue surged, led by growing U.S. sales of the company’s top drugs such as the erectile dysfunction pill Cialis and the diabetes treatment Humalog.
Profit excluding some items totaled 86 cents a share, the company said Tuesday in a statement, equaling an average of analysts’ estimates compiled by Bloomberg. Revenue rose 8.7 percent to $5.4 billion, topping estimates of $5.15 billion. The shares were little changed at $81.92 at 1:27 p.m. in New York trading.